Recent News About TYSABRI®

by

To the MS Community:

Biogen Idec and Elan thank the many people living with MS, their caregivers and physicians for your patience and support since the suspension of TYSABRI® (natalizumab) on February 28, 2005. Over the last several months, we have heard from patients who have expressed a range of emotions on TYSABRI including disappointment, fear and hope. This feedback has reminded us of the significant unmet need for new treatments, and motivated us to redouble our efforts to do even more to support people living with MS.

Following the suspension, we launched a comprehensive safety evaluation of TYSABRI patients in partnership with the world’s leading experts in progressive multifocal leukoencephalopathy (PML) and MS, as well as the National Institutes of Health (NIH). As you will recall, we suspended TYSABRI from the market and clinical trial dosing based on reports of PML, a rare and potentially fatal, demyelinating disease of the central nervous system. In October, we completed the safety evaluation, and were encouraged that the findings yielded no new confirmed cases of PML beyond the three previously reported.

More

Recent News About TYSABRI®

Press Release: FDA Advisory Committee Unanimously Recommends Reintroduction of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis (3/8/06)

Press Release: TYSABRI® Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine (3/1/06)

Press Release: TYSABRI® Multiple Sclerosis Clinical Trial Hold Lifted by FDA; Biogen Idec and Elan to Resume Clinical Trial Dosing in MS (2/15/06)

Press Release: Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI® for the Treatment of Multiple Sclerosis (1/23/06)

Letter to the MS Community (12/8/2005)

Press Release: Biogen Idec and Elan Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for TYSABRI® in Multiple Sclerosis (11/17/05)

Press Release: Elan and Biogen Idec Announce TYSABRI® Safety Evaluation Findings in Crohn’s Disease and Rheumatoid Arthritis Patients (10/17/05)

Press Release: Biogen Idec and Elan Submit Supplemental Biologics License Application to the FDA for TYSABRI® in Multiple Sclerosis (9/26/05)

Press Release: Elan and Biogen Idec Provide an Update on TYSABRI® (9/20/05)

Press Release: Biogen Idec and Elan Announce TYSABRI® Safety Evaluation Update (8/9/05)

Press Release: Two-Year Sentinel Data Evaluating TYSABRI® In Addition To AVONEX® Reinforce Efficacy In Multiple Sclerosis (7/18/05)

Press Release: TYSABRI® Phase III Induction Trial In Crohn’s Disease Meets Primary Endpoint (6/30/05)

Letter in the New England Journal of Medicine (6/9/2005)

Letter to the MS Community (4/27/2005)

Press Release: Positive One-Year Data From Sentinel Trial Evaluating Addition of TYSABRI® to AVONEX® Presented at American Academy of Neurology Meeting (4/13/05)

Press Release: TYSABRI® Two-Year Monotherapy Data Support Positive One-Year Efficacy Findings and Show Significant Reduction in Risk of Disability Progression (4/12/05)

Update to Dear Healthcare Professional Letter (3/30/05)

Press Release: Elan and Biogen Idec Announce Update on TYSABRI (3/30/05)

Update to Dear Healthcare Professional Letter (3/18/05)

Press Release: Biogen Idec and Elan Announce Update on TYSABRI (3/3/05)

Webcast on Voluntary Suspension of TYSABRI (2/28/05)

Press Release: Biogen Idec and Elan Announce Voluntary Suspension of TYSABRI (2/28/05)

Dear Healthcare Professional Letter (2/28/05)